01.03.24
MediLink Therapeutics has entered into a worldwide collaboration and license agreement with Roche for the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors.
MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink's ADC asset, YL211. MediLink will work with Roche's R&D unit China Innovation Center of Roche (CICoR) to initiate the Phase I clinical trial of YL211 and Roche will then take over the further development and commercialization globally. MediLink will receive upfront and near-term milestone payments totaling $50 million and, together with additional development, regulatory and commercial milestone payments potentially reaching a total deal value nearing $1 billion, as well as tiered royalties on future global annual net sales.
YL211 is an antibody-drug conjugate specifically targeting c-Mesenchymal-epithelial transition factor (c-Met), which belongs to the receptor tyrosine kinase (RTK) family. c-Met is closely associated with tumor formation, aggressive growth, and metastasis, making it a critical target for treating epithelial-mesenchymal transition. YL211, currently at IND stage, utilizes MediLink's TMALIN ADC platform technology, along with a highly specific c-Met antibody. It has demonstrated promising efficacy in various preclinical tumor models.
MediLink will grant Roche exclusive global rights for the development, manufacturing, and commercialization of MediLink's ADC asset, YL211. MediLink will work with Roche's R&D unit China Innovation Center of Roche (CICoR) to initiate the Phase I clinical trial of YL211 and Roche will then take over the further development and commercialization globally. MediLink will receive upfront and near-term milestone payments totaling $50 million and, together with additional development, regulatory and commercial milestone payments potentially reaching a total deal value nearing $1 billion, as well as tiered royalties on future global annual net sales.
YL211 is an antibody-drug conjugate specifically targeting c-Mesenchymal-epithelial transition factor (c-Met), which belongs to the receptor tyrosine kinase (RTK) family. c-Met is closely associated with tumor formation, aggressive growth, and metastasis, making it a critical target for treating epithelial-mesenchymal transition. YL211, currently at IND stage, utilizes MediLink's TMALIN ADC platform technology, along with a highly specific c-Met antibody. It has demonstrated promising efficacy in various preclinical tumor models.